Meta-analysisindependent cross-checkabstract checked★ key study I-AUTO-102 in-depth review
Drugs for relapsing multiple sclerosis
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
Overview
Gonzalez-Lorenzo M et al.. Cochrane Database Syst Rev 2024 · PMID 38174776 · DOI 10.1002/14651858.CD011381.pub3
Several MS drugs cut relapses roughly in half over two years compared with placebo.
Does the study support the specific claim? No · Methodological quality: high
Plain-language summary
Study explained simply
- What did the researchers want to find out?
Compare MS drugs.
- How was the study done?
Cochrane network meta-analysis.
- How many people, animals or samples were studied?
50 trials, 36,541 people.
- What was actually found?
Large relapse reductions with several DMTs.
- How large was the observed effect?
RR about 0.53-0.57 at 24 months.
- What do the results mean in everyday life?
MS treatment works; it should not be replaced by diet.
- What are the study's limitations?
Industry trials; short follow-up.
- What does it say about Elawady's specific claim?
Contradicts diet as replacement therapy.
- Do the results apply to Germany and Europe?
Applies; same physiology.
- What can explicitly not be concluded from this study?
Long-term disability beyond 2-3 years.
Scientific in-depth review
1. Full reference
- Authors
- Gonzalez-Lorenzo M et al.
- Journal
- Cochrane Database Syst Rev
- Year
- 2024
- Identifier
- PMID 38174776 DOI 10.1002/14651858.CD011381.pub3
- Verification
- verified – PubMed efetch 2026-10-26; Crossref update-to/updated-by check
- Retracted
- no
- Corrections
- none
- Extent checked
- abstract only
- Conflicts of interest and funding
Review authors' declarations in record; Cochrane funding via AIFA (stated).
2. Research question
Comparative efficacy and safety of disease-modifying therapies (DMTs) in relapsing-remitting MS.
3. Study design and population
- Study design
- Meta-analysis – Cochrane systematic review and network meta-analysis (GRADE)
- Population
Adults with RRMS
- Country
International
- Period
Search to Sept 2021; top-up Aug 2022
- Sample size
50 RCTs, 36,541 participants
- Inclusion and exclusion criteria
not stated in abstract
4. Methods and endpoints
- Exposure / intervention
DMTs (natalizumab, cladribine, alemtuzumab, fingolimod, etc.)
- Comparator
Placebo / other DMTs
- Endpoints
Relapses at 12/24/36 months, disability worsening, discontinuation, SAEs
- Statistical methods
Pairwise and network MA; RR/OR; GRADE
5. Actual results
- Results
Relapses at 24 months vs placebo: cladribine RR 0.53 (0.44-0.64), alemtuzumab 0.57 (0.47-0.68), natalizumab 0.56 (0.48-0.65) (high certainty); fingolimod 0.54, dimethyl fumarate 0.62, ponesimod 0.58 (moderate). Disability worsening at 24 months: natalizumab RR 0.59 (0.46-0.75; moderate). 68% of studies at high risk of 'other bias' due to sponsor role.
- Absolute risks
not reported
- Authors' conclusion
High confidence that 2-year treatment with natalizumab, cladribine or alemtuzumab decreases relapses more than other DMTs vs placebo; insufficient evidence beyond 2 years.
6. Strengths
- Cochrane NMA, large evidence base
- GRADE
7. Weaknesses
- Mostly industry-sponsored trials
- Little evidence beyond 2 years
8. Risk of bias
- Orienting tool
- AMSTAR 2
- Type of assessment
- simplified assessment (abstract only)
- Full formal assessment
- no
- Overall risk of bias
- low
- Rationale
Rigorous review; primary trials often industry-sponsored.
9. Assessment of the statistical interpretation
Large relative reductions (about 40-47%) in relapses; CIs log-consistent (stats/I-AUTO-102_ms_dmt.py).
10. Relevance to the specific claim
Shows MS has effective, specific drug treatments that roughly halve relapses - incompatible with the claim that MS is an arbitrary label for food reactions treated by diet.
11. Independent contrary findings
12. Transferability to Germany and Europe
Universal biology; applies in Europe and Egypt.
13. Overall methodological judgement
High-certainty evidence for drug treatment in MS.
| Multidimensional assessment | |
|---|---|
| Authenticity of the source | verified |
| Methodological quality | high |
| Risk of bias | low |
| Precision of results | high |
| Directness | direct |
| Reproducibility | replicated |
| Consistency with the overall evidence | consistent |
| Regional transferability | high |
| Adequacy of the interpretation (by the archive) | not applicable |